Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further treatment options, which currently lack a solid empirical basis, need to be taken account of in future investigations, such as the cannabinoids (Bhagavan et al., 2020), and tES or TMS (Krone et al., 2023).”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Bhagavan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
International Classification of Sleep Disorders-Third Edition
Sateia, M. J. (2014) · Chest · doi:10.1378/chest.14-0970 · Cited by 3,860
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
Comorbidity of Chronic Insomnia With Medical Problems
Taylor, D. J., Mallory, L. J., Lichstein, K. L., Durrence, H. H., Riedel, B. W., & Bush, A. J. (2007) · Sleep · doi:10.1093/sleep/30.2.213 · Cited by 875
(2009) · Sleep · doi:10.5665/sleep/32.1.55 · Cited by 664 · cited 1×
“In 2007, the financial burden of insomnia disorder was estimated to be over $US5000 per person annually for each individual with this condition [10], and data obtained in 1994 indicated a conservative estimate of $US92–107.”
BackgroundMedical and socio-professional impact of insomnia
Léger, D., Guilleminault, C., Bader, G., Lévy, E., & Paillard, M. (2002) · Sleep · doi:10.1093/sleep/25.6.621 · Cited by 468
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
Peever, J., & Fuller, P. M. (2017) · Current Biology · doi:10.1016/j.cub.2017.10.026 · Cited by 360
van der Zweerde, T., Bisdounis, L., Kyle, S. D., Lancee, J., & van Straten, A. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.08.002 · Cited by 336
The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c76f70 · Cited by 324
The assessment and management of insomnia: an update
Krystal, A. D., Prather, A. A., & Ashbrook, L. H. (2019) · World Psychiatry · doi:10.1002/wps.20674 · Cited by 256
Endocannabinoid signalling: has it got rhythm?
Vaughn, L. K., Denning, G., Stuhr, K. L., de Wit, H., Hill, M. N., & Hillard, C. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00790.x · Cited by 176
Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16)
Lintzeris, N., Driels, J., Elias, N., Arnold, J. C., McGregor, I. S., & Allsop, D. J. (2018) · Medical Journal of Australia · doi:10.5694/mja17.01247 · Cited by 101
Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors
Finlay, D. B., Sircombe, K. J., Nimick, M., Jones, C., & Glass, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00359 · Cited by 99
Eadie, J., van de Water, A. T., Lonsdale, C., Tully, M. A., van Mechelen, W., Boreham, C. A., Daly, L., McDonough, S. M., & Hurley, D. A. (2013) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2013.04.017 · Cited by 83
Research works printed but not linked: 33
- American Psychiatric Association. (Institution), American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM–5). 2012. · DOI · Paper page
- Macêdo P, Neves G, Poyares DLRD, da Gomes MMM, Macedo P, Neves G, et al. Insomnia current diagnosis: an appraisal. Rev Bras Neurol. 2015;51:62–8.
- Bollu P, Kaur H. Sleep medicine: insomnia and sleep. Mo Med. 2019;116(1):68–75.
- Bjorøy I, Jørgensen VA, Pallesen S, Bjorvatn B. The prevalence of insomnia subtypes in relation to demographic characteristics, anxiety, depression, alcohol consumption and use of hypnotics. Front Psychol. 2020;11:527. · DOI
- Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3:3–6.
- Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16:873–97.
- Cheung J, Ji X, Morin CM. Cognitive behavioral therapies for insomnia and hypnotic medications: considerations and controversies. Sleep Med Clin. 2019;14:253–65. · DOI
- Babson KA, Bonn-Miller MO. Sleep disturbances: implications for cannabis use, cannabis use cessation, and cannabis use treatment. Curr Addict Rep. 2014;1:109–14. · DOI
- Murillo-Rodríguez E. The role of the CB1 receptor in the regulation of sleep. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1420–7. · DOI
- Kesner AJ, Lovinger DM. Cannabinoids, endocannabinoids and sleep. Front Mol Neurosci. 2020;13:125. · DOI
- Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24:305–13. · DOI · Paper page
- Léger D, Debellemaniere E, Rabat A, Bayon V, Benchenane K, Chennaoui M. Slow-wave sleep: from the cell to the clinic. Sleep Med Rev. 2018;41:113–32. · DOI · Paper page
- Prospero-Garcia O, Amancio-Belmont O, Becerril-Melendez A, Ruiz-Contreras A, Mendez-Diaz M. Endocannabinoids and sleep. Neurosci Biobehav Rev. 2016;71:671–9. · DOI
- Garcia AN, Salloum IM. Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: a focused review. Am J Addict. 2015;24:590–8. · DOI · Paper page
- Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JDS, et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol. 2018;9:1–8. · DOI · Paper page
- Pertwee RG, Ross RA, Craib SJ, Thomas A. (−)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002;456:99–106. · DOI
- Carlini E, Cunha J. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21:417S-427S. · DOI · Paper page
- Zuardi AW, Guimaraes FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res Rev Bras Pesqui Med Biol. 1993;26:213–7.
- Bridgeman MBM, Abazia DDT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;42:180–8.
- Walsh Z, Callaway R, Belle-isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24:511–6. · DOI · Paper page
- Kuhathasan N, Dufort A, Mackillop J, Gottschalk R, Minuzzi L, Frey BN. The use of cannabinoids for sleep: a critical review on clinical trials. Exp Clin Psychopharmacol. 2019;27:383–401. · DOI · Paper page
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). 2013. · DOI · Paper page
- Buysse C, Reynolds F, Ill DJ, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–5. · DOI · Paper page
- Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19. · DOI · Paper page
- Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. · DOI · Paper page
- Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. · DOI · Paper page
- Smith S, Trinder J. Detecting insomnia: comparison of four self-report measures of sleep in a young adult population. J Sleep Res. 2001;10:229–35. · DOI · Paper page
- Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations—a review. Psychopharmacology. 1980;71:173–9. · DOI · Paper page
- Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.
- Cousens K, DiMascio A. Delta-9 THC as an hypnotic—an experimental study of three dose levels. Psychopharmacologia. 1973;33:355–64. · DOI
- Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23:18–041. · DOI · Paper page
- Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132:56–61. · DOI · Paper page
- Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34:587–91. · DOI · Paper page
Cited by
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
“Further treatment options, which currently lack a solid empirical basis, need to be taken account of in future investigations, such as the cannabinoids (Bhagavan et al., 2020), and tES or TMS (Krone et al., 2023).”
BackgroundSolmi, M., De Toffol, M., Kim, J. Y., Choi, M. J., Stubbs, B., Thompson, T., Firth, J., Miola, A., Croatto, G., Baggio, F., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072348 · Cited by 271
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
“However, a very recent SR and meta-analysis on the therapeutic use of cannabinoids does not indicate a beneficial effect on insomnia (Bhagavan et al., 2020).”
Background2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., et al. (2023) · Sleep Science · doi:10.1055/s-0043-1776281 · Cited by 25
“259 Another meta-analysis, with more than 5,000 patients, evaluated the impact of different cannabinoids onpatientswith sleepcomplaints under various medical conditions.”
Background
Metadata
- Authors
- Bhagavan, C., Kung, S., Doppen, M., John, M., Vakalalabure, I., Oldfield, K., Braithwaite, I., & Newton-Howes, G.
- ORCID
- Bhagavan, Chiranth
- Venue
- CNS Drugs
- Published
- 2020-11-26
- Volume
- 34
- Issue
- 12
- Pages
- 1217-1228
- ISSN
- 1172-7047
- 1179-1934
- Cited by
- 45
- References
- 18
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- Health Research Council of New Zealand (18/1002, 20/057)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.